Cardiff Oncology, Inc. Files Definitive Proxy Statement

TL;DR

<b>Cardiff Oncology, Inc. has filed its Definitive Proxy Statement for the period ending June 20, 2024, detailing executive compensation and corporate governance.</b>

AI Summary

Cardiff Oncology, Inc. (CRDF) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Cardiff Oncology, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 25, 2024. The filing covers the period ending June 20, 2024. The company's principal executive offices are located at 11055 Flintkote Avenue, San Diego, CA 92121. Cardiff Oncology, Inc. was formerly known as Trovagene, Inc. and XENOMICS INC. The filing includes details on executive compensation for the fiscal years 2021, 2022, and 2023.

Why It Matters

For investors and stakeholders tracking Cardiff Oncology, Inc., this filing contains several important signals. This DEF 14A filing provides shareholders with crucial information regarding upcoming annual meetings, director nominations, executive compensation, and other corporate actions, enabling informed voting decisions. Understanding the executive compensation structure and any proposed changes is vital for investors assessing management's alignment with shareholder interests and the company's financial health.

Risk Assessment

Risk Level: low — Cardiff Oncology, Inc. shows low risk based on this filing. The filing is a routine proxy statement and does not contain new financial performance data or significant strategic shifts, indicating a low level of immediate risk.

Analyst Insight

Review the executive compensation details and any proposed shareholder resolutions to assess management incentives and potential corporate governance changes.

Key Numbers

• 2024-06-20 — Reporting Period End Date (Conformed period of report)
• 2024-04-25 — Filing Date (Filed as of date)
• 2023-12-31 — Fiscal Year End (Fiscal year end)

Key Players & Entities

• Cardiff Oncology, Inc. (company) — Filer name
• DEF 14A (document) — Filing type
• 2024-04-25 (date) — Filing date
• 11055 Flintkote Avenue, San Diego, CA 92121 (address) — Business address
• Trovagene, Inc. (company) — Former company name
• XENOMICS INC (company) — Former company name

FAQ

Industry Context

Cardiff Oncology, Inc. operates in the biotechnology sector, focusing on the development of targeted therapies for cancer.

Regulatory Implications

As a publicly traded company, Cardiff Oncology is subject to SEC regulations, including the requirement to file proxy statements for shareholder meetings.

What Investors Should Do

1. Review the proxy statement for details on director nominations and voting procedures.
2. Analyze the executive compensation tables for information on salaries, bonuses, and equity awards for key executives.
3. Examine any shareholder proposals and management's recommendations for voting.

Key Dates

• 2024-04-25: Filing Date — Definitive Proxy Statement filed
• 2024-06-20: Reporting Period End — Period covered by the proxy statement

Year-Over-Year Comparison

This filing is a DEF 14A, which is a standard proxy statement. No prior filing details are available in the provided text for comparison.

Filing Documents

• crdf-20240425.htm (DEF 14A) — 840KB
• crdf-20240425_g1.jpg (GRAPHIC) — 56KB
• 0001628280-24-018143.txt (&nbsp;) — 1663KB
• crdf-20240425.xsd (EX-101.SCH) — 5KB
• crdf-20240425_def.xml (EX-101.DEF) — 6KB
• crdf-20240425_lab.xml (EX-101.LAB) — 10KB
• crdf-20240425_pre.xml (EX-101.PRE) — 6KB
• crdf-20240425_htm.xml (XML) — 155KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 18 PROPOSAL 2: RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR ENDING DECEMBER 31, 202 4 20 PROPOSAL 3: APPROVAL OF AN INCREASE TO THE NUMBER OF AUTHORIZED SHARES ISSUABLE UNDER THE CARDIFF ONCOLOGY 2021 OMNIBUS EQUITY PLAN 22 PROPOSAL 4: APPROVAL OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS 28

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 29 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 26 TRANSACTIONS WITH RELATED PERSONS 46 OTHER MATTERS 47 ADDITIONAL INFORMATION 47 APPENDIX A: CARDIFF ONCOLOGY, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN 49 PROXY CARD 64 3 Table of Contents Cardiff Oncology, Inc. 11055 FLINTKOTE AVENUE SAN DIEGO, CA 92121 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 20, 2024 The Board of Directors (the " Board ") of Cardiff Oncology, Inc. (" Cardiff " or the " Company ") is soliciting your proxy to vote at the Annual Meeting of Stockholders (the " Annual Meeting ") to be held at our offices, located at 11055 Flintkote Avenue, San Diego, CA 92121, on June 20, 2024, at 9:00 a.m. local time, including at any adjournments or postponements of the Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the Annual Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card if you received paper copies of the proxy materials, or follow the instructions below to submit your proxy over the Internet. In accordance with rules and regulations adopted by the U.S. Securities and Exchange Commission (the "SEC"), we have elected to provide our beneficial owners and stockholders of record access to our proxy materials over the Internet. Beneficial owners are stockholders whose shares of our common stock are held in the name of a broker, bank or other agent (i.e., in "street name"). Accordingly, a Notice of Internet Availability of Proxy Materials (the "Notice") will be mailed on or about May 10, 2024 to our beneficial owners and stockholders of record who owned our common stock at the close of business on April 22, 2024. Beneficial owners and stockholders of record will have the ability to access the proxy materials on a website referred to in the Not

View Full Filing

View this DEF 14A filing on SEC EDGAR